
    
      1. Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy,
           Damnhour University.

        2. All Participants agreed to take part in this clinical research and provide informed
           consent. for unconscious participants, the informed consent was obtained from their
           legally authorized representative.

        3. Patients with moderate to severe TBI will be enrolled from Tanta university hospitals.

        4. Serum samples will be collected for measuring the biomarkers.

        5. Our design is randomized, controlled study.

        6. All enrolled patients will be divided into 2 groups, Group (1) 25 patients that receive
           doxycycline 100 mg twice daily, either orally or through a nasogastric tube for 5 days,
           and group (2) will be 25 patients will receive placebo in addition to the standard
           treatment.

        7. All patients will be followed up during ICU period.

        8. Statsicial tests appropriate to the study design will be conducted to evaluate the
           significance of the results.

        9. Measuring outcome: the primary outcome is the change in the serum level of acute brain
           injury biomarkers.

       10. Results, conclusions, discussion and recommendations will be given.
    
  